You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA683
  • Published:  10 March 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate
  4. Expected publication

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 146 KB)

    Published:
    10 March 2021

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 223 KB)

    Published:
    04 February 2021
  • Committee papers (PDF 4.9 MB)

    Published:
    04 February 2021
  • Public committee slides (PDF 270 KB)

    Published:
    04 February 2021

Invitation to participate

  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 248 KB)

    Published:
    28 November 2019
  • Final scope (PDF 201 KB)

    Published:
    28 November 2019
  • Final stakeholder list (PDF 210 KB)

    Published:
    28 November 2019

Expected publication

  • TA557 Final scope (PDF 266 KB)

    Published:
    25 April 2024
  • TA557 Draft scope and provisional stakeholder list comments table (post-referral) (PDF 316 KB)

    Published:
    25 April 2024
  • TA557 Final stakeholder list (PDF 338 KB)

    Published:
    25 April 2024
  • TA557 Committee papers (PDF 14.19 MB)

    Published:
    25 April 2024
  • TA557 Final appraisal document (PDF 285 KB)

    Published:
    25 April 2024
  • Equality Impact Assessment (Guidance development) (PDF 222 KB)

    Published:
    25 April 2024
Back to top